GE Healthcare launches next generation Biacore(TM) molecular interaction analysis platform

CHALFONT ST. GILES, UK – 13 June 2016 – GE Healthcare’s Life Sciences business today launched the first of a next generation of BiacoreTM systems harnessing Surface Plasmon Resonance (SPR) technology. Biacore 8K marks the start of a new generation of Biacore systems maintaining the high data quality expected from Biacore at high throughput. New... Read more

Going Beyond Analog: GE Healthcare Launches Digital, Next-Generation Molecular Imaging Systems That Can Help Clinicians Advance Quantitative Care and Research

San Diego, CA – June 12, 2016 – GE Healthcare (NYSE:GE) showcased new molecular imaging technologies at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 that will enable clinicians to deliver personalized, quantitative results to patients. The Discovery MI system and Discovery NM/CT 670 CZT will help clinicians guide treatment, support patients with... Read more

PnuVax to acquire inactivated yellow fever vaccine intellectual property from GE Healthcare

CHALFONT ST. GILES, UK and KINGSTON, ONTARIO, CANADA – 8 June 2016 – PnuVax Incorporated (PnuVax), a vaccine and biopharmaceutical company, and GE Healthcare’s Life Sciences business (NYSE: GE) announced today that they have entered an agreement under which PnuVax can acquire GE Healthcare’s intellectual property (IP) relating to an inactivated yellow fever vaccine. Under... Read more